Literature DB >> 12197847

Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication.

B-S Sheu1, J-J Wu, C-Y Lo, H-W Wu, J-H Chen, Y-S Lin, M-D Lin.   

Abstract

AIM: To test whether supplements of Lactobacillus- and Bifidobacterium-containing yogurt (AB-Yogurt) affect the success of Helicobacter pylori eradication.
METHODS: One hundred and sixty H. pylori-infected patients were randomized into a triple-plus-yogurt group or a triple-only group, receiving 1 week of triple therapy with and without supplements of AB-Yogurt, respectively. In the triple-plus-yogurt group, AB-Yogurt was continued for 4 weeks after triple therapy. Eight weeks later, patients were assessed for the success of H. pylori eradication. The stool samples of 22 randomly selected patients, 11 from each group, were provided on enrolment, at the first week and at the fifth week for evaluation of the percentage of Bifidobacterium in anaerobes.
RESULTS: By intention-to-treat analysis, the triple-plus-yogurt group had a higher H. pylori eradication rate than the triple-only group (91% vs. 78%, P < 0.05). The per protocol H. pylori eradication rates were similar for both groups (93.5% vs. 89%, P = N.S.). Only patients supplemented with AB-Yogurt showed restoration of the percentage of Bifidobacterium in the anaerobes of stools at the fifth week to the level in the stools on enrolment.
CONCLUSIONS: Supplement with AB-Yogurt can improve the intention-to-treat eradication rates of H. pylori, and can restore the depletion of Bifidobacterium in stools after triple therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12197847     DOI: 10.1046/j.1365-2036.2002.01335.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  48 in total

1.  Probiotic Formulations: Application and Status as Pharmaceuticals-A Review.

Authors:  V Sreeja; Jashbhai B Prajapati
Journal:  Probiotics Antimicrob Proteins       Date:  2013-06       Impact factor: 4.609

2.  Probiotics-mixed messages.

Authors:  David R Mack
Journal:  Can Fam Physician       Date:  2005-11       Impact factor: 3.275

3.  Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone.

Authors:  J A da Silva Medeiros; T M F O Gonçalves; L Boyanova; M I de Correia Pereira; J N da Silva Paiva de Carvalho; A M de Sousa Pereira; A M Silvério Cabrita
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-05       Impact factor: 3.267

Review 4.  Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis.

Authors:  Min-Min Zhang; Wei Qian; Ying-Yi Qin; Jia He; Yu-Hao Zhou
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

5.  Posttreatment 13C-urea breath test is predictive of antimicrobial resistance to H. pylori after failed therapy.

Authors:  Ai-Wen Kao; Hsiu-Chi Cheng; Bor-Shyang Sheu; Ching-Yih Lin; Ming-Jen Sheu; Hsiao-Bai Yang; Jiunn-Jong Wu
Journal:  J Gen Intern Med       Date:  2005-02       Impact factor: 5.128

Review 6.  Clinical practice: diagnosis and evaluation of dyspepsia.

Authors:  David Yates Graham; Massimo Rugge
Journal:  J Clin Gastroenterol       Date:  2010-03       Impact factor: 3.062

7.  Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice.

Authors:  Kathene Candace Johnson-Henry; David J Mitchell; Yaron Avitzur; Esther Galindo-Mata; Nicola L Jones; Philip M Sherman
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

Review 8.  Efficacy of fermented milk and whey proteins in Helicobacter pylori eradication: a review.

Authors:  Aarti Sachdeva; Swapnil Rawat; Jitender Nagpal
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

Review 9.  Probiotics and human health: a clinical perspective.

Authors:  H S Gill; F Guarner
Journal:  Postgrad Med J       Date:  2004-09       Impact factor: 2.401

10.  Lactobacilli inhibit interleukin-8 production induced by Helicobacter pylori lipopolysaccharide-activated Toll-like receptor 4.

Authors:  Chao Zhou; Feng-Zhen Ma; Xue-Jie Deng; Hong Yuan; Hong-Sheng Ma
Journal:  World J Gastroenterol       Date:  2008-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.